Huge thank you to our incredible faculty, attendees, sponsors, and GlomCon instructors for making #GlomConHawaii conference a success! 🌟 We deeply appreciate and value your partnership. Hope to see you all next year, in Maui August 3-7 ⭐️ Mahalo!! 🌺 @glomcon.org

Huge thank you to our incredible faculty, attendees, sponsors, and GlomCon instructors for making #GlomConHawaii conference a success! 🌟 We deeply appreciate and value your partnership. Hope to see you all next year, in Maui August 3-7 ⭐️ Mahalo!! 🌺

What a fantastic evening at the #GlomConHawaii reception! Thank you to everyone who joined us🥰 It’s a privilege to be part of such an exceptional community. The future of nephrology is bright. @glomcon.org

Excellent thread below I will also plug this talk by Paola Romagnani on podocytopathies youtu.be/bRMeqaGgA9I?... #GlomCon #NephGR

Register here 👉 glomconhawaii.org #GlomConHawaii2025 #GlomConHawaii #GlomCon

This year’s in-person gathering promises to strengthen connections, spark deeper collaboration, and elevate the learning experience in beautiful Hawaii. Can't join us in person? We plan to live-stream the main sessions; see you on the virtual side. #GlomConHawaii #GlomCon

Clinical Endpoints for Glomerular Diseases from @hjanders.bsky.social #GlomConHawaii 🌊 #Nephpearls #NephSky

IgA Nephropathy #IgAN: An Overview of the Clinical Trials ca. 2025 from @saynanorouzi.bsky.social #Nephpearls #NephSky www.kidneymedicinejournal.org/article/S259...

Congrats @sophia-kidney.bsky.social @saynanorouzi.bsky.social @kashvilunawat.bsky.social And all the other awardees of the @asnkidney.bsky.social NephCure grants! www.kidneycure.org/pages/qa.aspx

It’s not just the immune mediated and infections - we need to pay attention to cardiovascular disease in SLE pubmed.ncbi.nlm.nih.gov/40539000/ Nice job synthesizing the data @saynanorouzi.bsky.social and team! #NephSky #lupuschat

#GlomConHawaii 2025 🌴🌊 session: Post-market Evaluations, Registries, and RWE Studies Register here 👉 glomconhawaii.org #GlomConHawaii2025 #GlomConHawaii #GlomCon

@saynanorouzi.bsky.social rocks in Vienna #ERA25! @glomcon.org

🚨 Exciting News! 🚨 The GlomCon Foundation, American Kidney Fund, and IgA Nephropathy Foundation have joined forces to develop the consensus framework for establishing Centers of Excellence in Glomerular Disease Care! 🔗 Learn more: www.glomcon.org/news-release...

Applications are now open for the Polycystic Kidney Disease Medical Directorship Program (PKD-MDP)! 🤩 🔗 Apply here: www.glomcon.org/pkdmd-program 📅 Deadline to apply is July 15, 2025

Q1 was full of important advances in #nephrology, especially in glomerular diseases. Hear from @SaynaNorouzi @LLUHealth @GlomCon as she reflects on some of these developments and looks ahead to what might be in store for the rest of 2025: www.hcplive.com/view...#nephrology,

Are you effectively preventing VTE in your patients with nephrotic syndrome? Check out our paper below on KI reports about this important topic. It's a fantastic collaboration with some truly brilliant minds! #NephSky @glomcon.org www.kireports.org/article/S246...

GlomCon is thrilled to introduce a new leadership training opportunity 🤩 The Polycystic Kidney Disease Medical Directorship Program (PKD-MDP) is a year-long, interactive program aiming to deepen participants' expertise in PKD diagnosis and management. Applications open May 1.

Smoking-modified HTN-associated nodular glomerulosclerosis (SHaNGS), a form of hypertensive glomerulosclerosis in the context of alteration by smoking products. pmc.ncbi.nlm.nih.gov/articles/PMC11…

Venous Thromboembolism Prevention in Nephrotic Syndrome: The Role of Aspirin, Vitamin K Antagonists, and Direct Oral Anticoagulants ca. 2025 from @kireports.bsky.social @saynanorouzi.bsky.social @kdjhaveri.bsky.social #Nephpearls #NephSky 👉 www.kireports.org/article/S246...

In August 2024, GlomCon launched its 1st international hybrid conference on GN in Maui. Diverse group of expert faculty of 52 members, achieving an intentional and balanced gender representation of 50% male and 50% female. The event reached a total of 619 registrations. karger.com/gdz/article/5/…

The FDA approved inebilizumab-cdon (UPLIZNA; @Amgen as the first and only treatment for adult patients diagnosed with immunoglobulin G4-related disease (IgG4-RD). #RareDiseases pubmed.ncbi.nlm.nih.gov/39969992/

Thank you, @khon2news.bsky.social News for inviting us this morning to discuss Rare Kidney Disease and the @nkf-professionals.bsky.social (Hawaii). ⭐️ Join us for the NKF Hawaii Kidney walk on Saturday🤍#PatientAdvocacy #RareKidneyDiseases kidneywalk.org/hawaii

𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗡𝗲𝘄𝘀! GlomCon has convened an international expert panel to develop criteria for Centers of Excellence—and we’ll share the findings at #GlomConHawaii2025. Stay tuned for more updates on our new clinics and workshop! #GlomCon

Your generosity during #NationalKidneyMonth will be matched dollar-for-dollar, up to $50,000. That means your gift will have twice the power to change lives and bring hope to those affected by kidney disease. Make an impacthttps://buff.ly/41htQVh

T3d: Here are the trials with cell B blockers (yeah, induction, refractory LN, or whatever). Any notable differences in their design? #nephjc

🚨Such a timely initiative by GlomCon🎉 Over the past 5 years, GlomCon has inspired and trained more than 500 future glomerular disease experts. Let's collaborate to define Centers of Excellence and enhance patient access to specialized care! #GlomerularDisease

🚨Should we consider a new approach to enhance prognostication in PKD? See our editorial on CJASN ⭐️👇 @asnkidney.bsky.social #endPKD @pranavgarimella.bsky.social @ucsdhealthsci.bsky.social journals.lww.com/cjasn/Fullte...

AJKD Atlas of Renal Pathology: Crystalglobulin-Induced Nephropathy bit.ly/41jvO7T (FREE) #RenalPath

Did you know that March 13 is #WorldKidneyDay? More people than ever are at risk for kidney disease, and your generosity today can change lives. Make your first monthly gift now and see it matched, dollar-for-dollar, up to $50,000. Make your impact: buff.ly/41iCpPV

Are you effectively preventing VTE in your patients with nephrotic syndrome? Check out our paper below on KI reports about this important topic. It's a fantastic collaboration with some truly brilliant minds! #NephSky @glomcon.org www.kireports.org/article/S246...

Rounds on Sunday are way more fun when I’m taking notes with my magical pen! 😃✨ Glomerular disease clinics 🥰🤍 #RareDiseases #SavingKidneys @glomcon.org

Quiz: Young man with 1 week of fever, headaches, nonproductive cough, 1 day of dyspnea. Within 36 hours, he had 1 episode of hemoptysis and worsening hypoxia requiring mechanical ventilation. https://bit.ly/4ka9Ts3 (FREE)

IgG4-related kidney disease needs timely diagnosis and management #RareDisease #Glomlovers See our paper 👇 A wonderful collaboration with this amazing team @glomcon.org @asnkidney.bsky.social pubmed.ncbi.nlm.nih.gov/39969992/

Monday morning 7 AM 😃😉 Second day of Hafa Adai conference #NephSky #Guam Started the day with 30 minute of yoga in the balcony with this view ✈️🥰

Monoclonal Gammopathy of Renal Significance (MGRS) by the expert Dr. Zand @GlomCon Fellowship Program ⭐️ #Glomlovers #NephSky

BREAKING NEWS: The FDA has approved Ozempic for patients with chronic kidney disease. This means the popular injection can be used to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular disease in patients with chronic kidney disease and diabetes.

Next month, I will be moderating a case-based discussion on IgA nephropathy at HCPLive. It's a timely conversation about the available therapies for this condition. Really excited ⭐️😍 #Nephsky You can sign up here (Free registration):👇 event.hcplive.com/event/4e2c7f...

⭐️The First International Hybrid Glomerular Diseases Conference: GlomCon Hawaii ⭐️ Now Published 👇#NephSky #glomlovers @glomcon.org 🚨pubmed.ncbi.nlm.nih.gov/39827877/

Core Curriculum by Layana T. Takieddine and Joe M. El-Khoury: Laboratory Anomalies in the Basic Metabolic Panel https://bit.ly/42cNzri (FREE)

Dr. Sethi ⭐️delivered an outstanding lecture at the @glomcon.org fellowship program this morning. By the end of the session, the fellows were asking for another lecture with him.🤍😉 #Nephsky

Effective patient-physician communication to improve health-related quality of life and adherence to treatment plan⭐️ See our recent paper @JournalofNeph link.springer.com/article/10.100…#Nephskyky

Thank you Docwire for highlighting our upcoming Rare Kidney Disease conference. docwirenews.com/post/loma-li... Almost 350 registrations; 121 in-person Still have time to register here 👇 www.eeds.com/portal_live_...

A reality check eGFR; IgAN treatment options by Dr. Rovin @glomcon.org fellowship program #GlomLovers ⭐️👌👇

Happy New Year!! How to start 2025?! With an amazing lecture by Dr. Rovin ⭐️🤯 @glomcon.org Fellowship program. 🚨New FDA approved meds for IgAN 🚨Love-hate relationship with steroids Nothing lasts forever 😄😉 #Glomlovers

And just like that…the final sunset of 2024! Wishing you a Happy New Year! ⭐️🧿❤️

Editorial by Jung-Im Shin, Antoine Créon, and Juan-Jesus Carrero: Metformin in People With Diabetes and Advanced CKD: Should We Dare? https://bit.ly/3P4BPzy (FREE)

Calcium oxalate crystals in the #UrinarySediment from a pt presenting with serum pH 6.90, HCO3 9, AG 29 and plasma Osm 352. Ethylene glycol tox. Got fomepizole, RRT. Current metabolic state normalized, but still AKI-RRT an on MV. @nephrotox.bsky.social

Counting down the Top Ten #AJKDBlog posts of 2024: Commentary by George Vasquez Rios: 7️⃣ Simple Kidney Cysts Not So Simple After All: Exploring the Connection Between Simple Kidney Cysts and Post-Nephrectomy Kidney Function Decline https://bit.ly/3Xmc2aU (FREE) @pascale-khairallah.bsky.social

Enrollment for the 2025 Kidney Pathology Certificate Program is now open! 👉 Pre-registration is required before enrollment: ikgplk7aacm.typeform.com/kpcp2025 For questions, reach out to [email protected] #GlomCon